What does NEWHOUSE PHARMACEUTICALS do?

NEWHOUSE PHARMACEUTICALS is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 11 January 2018, 1 establishment.

What is the address of NEWHOUSE PHARMACEUTICALS?

The registered office of NEWHOUSE PHARMACEUTICALS is located at Meensesteenweg 82, 8870 Izegem.

Is NEWHOUSE PHARMACEUTICALS still active?

Yes. According to the CBE (19 September 2026) NEWHOUSE PHARMACEUTICALS is active, legal situation “Normale toestand”, started on 11 January 2018.

Is NEWHOUSE PHARMACEUTICALS registered on Peppol?

Yes, NEWHOUSE PHARMACEUTICALS is registered on the Peppol network with ID 0208:0687802947.

What is the enterprise number of NEWHOUSE PHARMACEUTICALS?

The enterprise number of NEWHOUSE PHARMACEUTICALS is BE0687802947.

When was NEWHOUSE PHARMACEUTICALS founded?

NEWHOUSE PHARMACEUTICALS was founded on 11 January 2018.

Who are the directors of NEWHOUSE PHARMACEUTICALS?

According to the 2025 annual accounts, the directors of NEWHOUSE PHARMACEUTICALS are: Thomas VANNIEUWENHUYSE.

Is NEWHOUSE PHARMACEUTICALS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 January 2018; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did NEWHOUSE PHARMACEUTICALS make in 2025?

NEWHOUSE PHARMACEUTICALS posted a profit after taxes of € 142,769 in financial year 2025.

What is the revenue of NEWHOUSE PHARMACEUTICALS?

As a small company, NEWHOUSE PHARMACEUTICALS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 243,266.

NEWHOUSE PHARMACEUTICALS (Private Limited) - Izegem

Dossier NEWHOUSE PHARMACEUTICALS, printed on 19 September 2026 from databakkes.be/en/0687802947/newhouse-pharmaceuticals. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 39 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

NEWHOUSE PHARMACEUTICALS from Izegem, company number BE0687802947, closed financial year 2025 with a result of € 142,769 after tax. For that financial year NEWHOUSE PHARMACEUTICALS recorded a gross margin of € 243,266 and equity of € 1.3 million. Compared with financial year 2024, the result moved from € 112,764 to € 142,769. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 25, 2026.

What it is worth Growing

€ 1.3 million

▲ 9% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 142,769

▲ 27% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 29,115

▲ € 29,013 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 40,000 paid out

28 % of the profit went to the shareholders, the rest stayed in the company.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.3 million

▼ 7% vs 2024

€ 243,794 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 7,781

▼ 30% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 25,703

▼ 43% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 167,946 Gross margin 2022: € 167,946 First fiscal year in the series	€ 225,817 Gross margin 2023: € 225,817 ▲ 34% vs 2022 (€ 167,946) Favourable step	€ 206,397 Gross margin 2024: € 206,397 ▼ 9% vs 2023 (€ 225,817) Unfavourable step	€ 243,266 Gross margin 2025: € 243,266 ▲ 18% vs 2024 (€ 206,397) Favourable step	▲ 18%
Profit after taxes	€ 100,733 Profit after taxes 2022: € 100,733 First fiscal year in the series	€ 123,333 Profit after taxes 2023: € 123,333 ▲ 22% vs 2022 (€ 100,733) Favourable step	€ 112,764 Profit after taxes 2024: € 112,764 ▼ 9% vs 2023 (€ 123,333) Unfavourable step	€ 142,769 Profit after taxes 2025: € 142,769 ▲ 27% vs 2024 (€ 112,764) Favourable step	▲ 27%
Equity	€ 1,011,569 Equity 2022: € 1,011,569 First fiscal year in the series	€ 1,109,901 Equity 2023: € 1,109,901 ▲ 10% vs 2022 (€ 1,011,569) Favourable step	€ 1,192,665 Equity 2024: € 1,192,665 ▲ 7% vs 2023 (€ 1,109,901) Favourable step	€ 1,295,433 Equity 2025: € 1,295,433 ▲ 9% vs 2024 (€ 1,192,665) Favourable step	▲ 9%
Total debts	€ 1,631,754 Total debts 2022: € 1,631,754 First fiscal year in the series	€ 1,542,933 Total debts 2023: € 1,542,933 ▼ 5% vs 2022 (€ 1,631,754) Favourable step	€ 1,466,425 Total debts 2024: € 1,466,425 ▼ 5% vs 2023 (€ 1,542,933) Favourable step	€ 1,363,651 Total debts 2025: € 1,363,651 ▼ 7% vs 2024 (€ 1,466,425) Favourable step	▼ 7%
Cash	€ 21,347 Cash 2022: € 21,347 First fiscal year in the series	€ 10,777 Cash 2023: € 10,777 ▼ 50% vs 2022 (€ 21,347) Unfavourable step	€ 102 Cash 2024: € 102 ▼ 99% vs 2023 (€ 10,777) Unfavourable step	€ 29,115 Cash 2025: € 29,115 ▲ € 29,013 vs 2024 (€ 102) Favourable step	▲ € 29,013
Retained profit	€ 836,569 Retained profit 2022: € 836,569 First fiscal year in the series	€ 934,901 Retained profit 2023: € 934,901 ▲ 12% vs 2022 (€ 836,569) Favourable step	€ 1,017,665 Retained profit 2024: € 1,017,665 ▲ 9% vs 2023 (€ 934,901) Favourable step	€ 1,120,433 Retained profit 2025: € 1,120,433 ▲ 10% vs 2024 (€ 1,017,665) Favourable step	▲ 10%
Dividend	€ 50,000 Dividend 2022: € 50,000 First fiscal year in the series	€ 25,000 Dividend 2023: € 25,000 ▼ 50% vs 2022 (€ 50,000) Unchanged	€ 30,000 Dividend 2024: € 30,000 ▲ 20% vs 2023 (€ 25,000) Unchanged	€ 40,000 Dividend 2025: € 40,000 ▲ 33% vs 2024 (€ 30,000) Unchanged	▲ 33%
Bank debt	€ 1,534,944 Bank debt 2022: € 1,534,944 First fiscal year in the series	€ 1,451,261 Bank debt 2023: € 1,451,261 ▼ 5% vs 2022 (€ 1,534,944) Favourable step	€ 1,364,646 Bank debt 2024: € 1,364,646 ▼ 6% vs 2023 (€ 1,451,261) Favourable step	€ 1,274,389 Bank debt 2025: € 1,274,389 ▼ 7% vs 2024 (€ 1,364,646) Favourable step	▼ 7%
Balance sheet total	€ 2,643,323 Balance sheet total 2022: € 2,643,323 First fiscal year in the series	€ 2,652,835 Balance sheet total 2023: € 2,652,835 Unchanged (€ 2,643,323) Unchanged	€ 2,659,089 Balance sheet total 2024: € 2,659,089 Unchanged (€ 2,652,835) Unchanged	€ 2,659,085 Balance sheet total 2025: € 2,659,085 Unchanged (€ 2,659,089) Unchanged

Key figures of NEWHOUSE PHARMACEUTICALS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to NEWHOUSE PHARMACEUTICALS?

What happened at NEWHOUSE PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 25, 2026 New annual accounts for financial year 2025: profit of € 142,769 (▲ 27% vs 2024). filed late Source: NBB ↗
Jan 11, 2018 New establishment in Izegem. KBO
Jan 11, 2018 Start of the company according to the CBE. KBO

In short

From € 100,733 profit in 2022 to € 142,769 profit in 2025.

Paid € 191,252 in corporate taxes since 2022.

Best year ever: 2025, with € 142,769 profit.

Paid out € 145,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at NEWHOUSE PHARMACEUTICALS? We notify you, reason included.

Follow NEWHOUSE PHARMACEUTICALS

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Thomas VANNIEUWENHUYSE

NEWHOUSE PHARMACEUTICALS

Loma Pharma 100%

Behind NEWHOUSE PHARMACEUTICALS is Thomas VANNIEUWENHUYSE. It owns 100% of Loma Pharma itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Thomas VANNIEUWENHUYSE

Director

Also active at: LOMA PHARMA

Establishments

Establishment units

Physical locations of this company

Registered office

Meensesteenweg 82

8870 Izegem

2.272.945.669

Ten Bosstraat 5

8870 Izegem

Active since 11 January 2018

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

LOMA PHARMA same network

€ 420,865 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0687.802.947

VAT number

BE 0687.802.947

Registered office

Meensesteenweg 82, 8870 Izegem

Names & denominations

NEWHOUSE PHARMACEUTICALS

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

11 January 2018

Peppol

Active · Active since 18 Nov 2025

Activities · NACE

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

NEWHOUSE PHARMACEUTICALS

Warning lights

Financials

What happened to NEWHOUSE PHARMACEUTICALS?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions